| Bioactivity | GSK-2793660 (free base) is an oral, irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 (free base) can be used for the research of bronchiectasis[1][2]. |
| Target | Cathepsin C (CTSC) |
| In Vivo | GSK-2793660 (free base) is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1]. |
| Name | GSK-2793660 free base |
| CAS | 1613458-70-0 |
| Formula | C20H27N3O3 |
| Molar Mass | 357.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Szcześniak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016 Feb 5;81(3):1057-74. [2]. Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820. |
GSK-2793660 free base
CAS: 1613458-70-0 F: C20H27N3O3 W: 357.45
GSK-2793660 (free base) is an oral, irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 (free base) can be used fo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.